CEACAM5 and pulmonary alveolar proteinosis: With regard to change from baseline in biomarkers with the potential for early detection of pulmonary alveolar proteinosis (carcinoembryonic antigen, KL-6, and SP-D), there were no trends associated with namilumab treatment.